In a model of experimental asthma, VISTA deficiency and blockade exacerbated Th2 responses and type II immunity (11, 22), whereas an anti-VISTA agonistic antibody reduces disease severity and suppressed lung inflammation (22). Here, VSIR is linked to asthma.